Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies.
Ricardo AlonsoMagdalena CasasLuciana LazaroNora Fernandez LiguoriCecilia PitaLeila CohenJuan Ignacio RojasAgustín PappollaLiliana PatruccoEdgardo CristianoMarcos BurgosCarlos VrechRaul PiedrabuenaLopez PabloNorma DeriGeraldine LueticJimena MiguezMariela CabreraAlejandra MartinezGisela ZangaVerónica TkachukSantiago TizioEdgar Carnero ContenttiEduardo KnorreFelisa LeguizamonCarolina MainellaPedro NofalSusana LiwackiJavier HrybMaria MenichiniClaudia PestchankerMarina AlonsoOrlando GarceaBerenice Anabel SilvaPublished in: Multiple sclerosis journal - experimental, translational and clinical (2023)
We found a high proportion of patients who achieved NEDA-3 at 1 and 2 years. Early high-efficacy strategy patients had a higher probability of achieving NEDA-3 at 2 years.